Trialect

+ More Filters

Reset Filters

Specialty

Funding Organization

Funding Type

Eligible Country

Deadline

From

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

High-Risk/High-Impact Grant Program

Osteosarcoma Institute

To dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science.

HISTORY The Osteosarcoma Institute (OSI) was established in 2017 with the goal of improving the outcomes of patients with osteosarcoma. It was envisioned by the What Would Willie Want (QuadW) Foundation, which was created in 2005 to honor the memory of Willie Tichenor, who lost his life to osteosarcoma at age 19. QuadW convened a conference in 2015 to challenge experts in osteosarcoma research to expedite work that could improve outcomes. This meeting led to the formation of the OSI, with a foundational grant from QuadW.

GRANT STRATEGY The OSI is a science-driven organization whose strategy is guided by its active and engaged Strategic Advisory Board of preeminent physicians and other researchers from academia and industry. In pursuit of its mission, the OSI employs a multifaceted strategy in which grant funding plays an important role. Our grant programs provide both immediate hope to patients through clinical trials and long-term hope through earlier-stage translation of scientific ideas that have the potential to result in a new treatment. Our correlative science grants are designed to answer critical questions that are too often ignored during clinical trials due to lack of funds: Is the drug under study having the biological effect in patients that it was hypothesized to have based on preclinical data? If not, why not? With this information, even a failed clinical trial can point the way to an advance. Our fourth category, High Risk/High Impact grants, exists to enable the study of novel, untested but intriguing ideas that would otherwise be rejected by the customary, risk-averse criteria of grant proposal evaluation. The objective of all our preclinical grants is to identify and advance scientific ideas toward the clinic. Today, the OSI has committed $6.5 million toward a comprehensive portfolio of 14 funded studies. We maintain a high level of involvement and accountability with our grantees through regular and rigorous progress reporting.

SCOPE OF PROPOSAL Grantmaking involves balancing the potential impact of a successful research project with the risk of experimental failure. Traditionally, risk mitigation is accomplished during the research proposal review process in several ways, including heavily weighing preliminary data. While the historical balance point has proven broadly effective and successful, the stubborn lack of progress in osteosarcoma suggests that alternatives should be considered. Thus, the aim of this grant program is to place less emphasis on preliminary data in order to encourage projects exploring bold innovations that may fall within any stage of the drug development path, and that seek to deliver curative outcomes to patients with osteosarcoma. Proposals will be most valued based on their innovation and sound scientific hypothesis, and the likelihood that the approach will address a true dependency in osteosarcoma. The desired criteria for this high-risk/high-impact osteosarcoma drug development research are:

• Bold ideas that will generate evidence of success or failure within 12 months.

• A new research direction rather than a continuation of ongoing funded research.

• While preliminary data are not required, the applicant must demonstrate feasibility of a persuasive research plan.

• Rigorous, quarterly interactive grant progress reviews to be used to guide ongoing direction and distribution of research support. A successful high-risk/high-impact grant proposal should have one or more of the following characteristics:

• A proposal that, upon successful conclusion of the project, may mature into a successful submission for a traditional OSI grant or launch a translational development plan with investigators, institutions, or commercial biopharma companies.

• An existing relationship that makes the development of a therapeutic asset in biopharma feasible.

BUDGET From $25,000 – $125,000 total over one year (inclusive of indirect costs not to exceed 10% of the requested project budget).

INDIRECT COSTS Indirect costs cannot exceed 10% of the total OSI requested funding AND budgets may not exceed the amounts stated above in the grant program descriptions inclusive of indirect costs. In other words, no more than 10% of the OSI’s funds can go to indirect costs. Also, we do not use the Modified Total Direct Cost base.

APPLICATION SUBMISSION INSTRUCTIONS First time users must register as a new user in ProposalCentral to begin the application process. The recommended browsers for accessing the application are Google Chrome and Mozilla Firefox. Only applicants who submit an LOI and are approved may submit a full proposal. The PI will be notified via email if the LOI is approved or rejected. If approved, the PI will then have access to the full proposal in ProposalCentral. The PI who submits the LOI should be the same PI that submits the full proposal. To locate the OSI Grant Programs, select the “Grant Opportunities” tab and enter “Osteosarcoma Institute” in the search box. The application form is available by clicking “Apply Now” on the appropriate line for the following grant programs:

• High-Risk/High-Impact Grant Program

Note: Access can be granted to other users by using the “Enable other users to access this proposal” link.

FORMATTING INSTRUCTIONS FOR ATTACHMENTS

• Calibri or Times New Roman Font (minimum 11-point font for text and no smaller than 9-point font for figures, legends, and tables).

• Single-spaced text is acceptable, and space between paragraphs is recommended.

• In the Project Description, pages must be numbered consecutively.

• 0.75-inch minimum margin.

• Only PDF files are accepted.

CONTACTS

• ProposalCentral Customer Support: pcsupport@altum.com / Phone: 800.875.2562

• The Osteosarcoma Institute: submissions@osinst.org

Specialties

Cancer

Orthopedics

Oncology

Eligibility Requirements

• Funds must be granted to nonprofit/charitable institutions or organizations.

• Grantee organization does not need to be based in the United States.

o However, in order to fund a foreign entity, the OSI requires documentation that if the entity were a United States-based organization, the entity would qualify as a charitable organization. This is usually relatively straightforward when dealing with entities in countries with a tax regime similar to the U.S. by way of a government-issued letter or other document designating the entity as a charitable institution or as performing a charitable purpose (for example, research or education). It might also be a determination from the relevant taxing authority that the entity qualifies for tax-deductible contributions.

• Applicants need not be United States citizens.

• Applicants must have an MD, PhD, MD/PhD, or equivalent and be appointed as faculty (or equivalent) at an academic institution.

• Applicants must have a track record of publication and funding productivity that demonstrates the project can be accomplished by the investigators.

• Research projects may be an extension of ongoing research but cannot overlap with any funded studies unless the applicant clearly demonstrates that new funding will not duplicate existing support.

• Applicants can submit only one (1) Letter of Intent (LOI).

• Applicants selected for funding will permit the OSI to publicize the grant for fundraising purposes, including, but not limited to a five-minute video discussing the research project, photos of lab, and photos of children participating in clinical trials, where applicable.

• Applications that do not follow the specific grant application instructions and/or submission process will not be considered.

• Applications received after the due date will not be considered.

• Applications which do not fall under the OSI mission will not be considered.

• Resubmissions: Only one resubmission of a previously reviewed application is permitted.

Sponsor Details

Sponsor Institute/Organizations: Osteosarcoma Institute

Address: 3963 Maple Avenue Suite 390 Dallas, TX 75219, ph. 972.903.8408

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity